Results 241 to 250 of about 25,202 (260)
Some of the next articles are maybe not open access.
Clinical Pharmacokinetics of Dapsone
Clinical Pharmacokinetics, 1986Dapsone (DDS) has for about 4 decades been the most important antileprosy drug. Concentrations of dapsone and its monoacetyl metabolite, MADDS, can be determined in biological media by high-performance liquid chromatography. After oral administration, the drug is slowly absorbed, the maximum concentration in plasma being reached at about 4 hours, with ...
F. W. H. M. Merkus +2 more
openaire +2 more sources
Archives of Dermatology, 1985
To the Editor.— Dapsone (4,4′-diaminodiphenylsulfone) causes dose-limiting hemolysis and methemoglobinemia, with formation of Heinz bodies (denatured hemoglobin particles) and characteristic poikilocytes.1It has been proposed that Heinz body testing during dapsone treatment might be useful2; we have found it to be of restricted value.
Michael H. Rosove +2 more
openaire +3 more sources
To the Editor.— Dapsone (4,4′-diaminodiphenylsulfone) causes dose-limiting hemolysis and methemoglobinemia, with formation of Heinz bodies (denatured hemoglobin particles) and characteristic poikilocytes.1It has been proposed that Heinz body testing during dapsone treatment might be useful2; we have found it to be of restricted value.
Michael H. Rosove +2 more
openaire +3 more sources
, 2005 Dapsone (4,4'-diaminodiphenylsulphone) has been in clinical use for more than 60 years. It is widely used in the treatment of a variety of infectious diseases, including leprosy and malaria, and it has some action against other parasites. In addition, it has been effective in the treatment of a diversity of cutaneous disorders, particularly those ...
David Bacman +2 more
openaire +1 more source